Oncology
Lung
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation: A Randomized Phase II Trial in Small-Cell Lung Cancer (MAVERICK).
- Study ID: SWOG S1827
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (LU008)
- Study ID: NRG LU008
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants with Non-Small Cell Lung Cancer (INTerpath-002)
- Study ID: V940-002
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Environmental
A Pilot of a Randomized, Pragmatic Trial of Cancer-Directed Therapy Administration in the Patients’ Homes Versus in Clinic
- Study ID: CCBW
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Breast
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
- Study ID: MK2870-032
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery.
- Study ID: MK2870-012
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
- Study ID: CCTG MA.39
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastaic ER+/HR2- Breast Cancer with an ESR1 Mutation
- Study ID: Elaine 3 Study
- Principal Investigator: Grant Seeger
- Status: Enrolling
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER 2-, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Study ID: NRG- BR007
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Prostate
Parallel Phase III Randomized Trial of Genomic- Risk Stratefied Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (Guidance)
- Study ID: NRG-GU010
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Parallel Phase III Randomized Trial for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
- Study ID: NRG-GU009
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Phase III Five Fraction Radiation for High-Risk Prostate Cancer (HIGH FIVE TRIAL)
- Study ID: NRG-GU013
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (MCrPC), Stratified by Aggressive Variant Signature
- Study ID: SWOG S2312
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Gastrointestinal
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease (Circulate- North America)
- Study ID: NRG-GI008
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Gynecologic
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Study ID: ECHO
- Principal Investigator: Collette Lessard, MD
- Status: Enrolling
